newsfilter
← Latest News
GlobeNewswire·

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

– The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Topline